NEW YORK, Feb. 21, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, has advised that it is issuing a new Request for Proposal, number 11-100-SOL-00007, seeking to procure 1.7 million courses of a smallpox antiviral. The Request for Proposal also proposes that the contract would contain an option to procure up to 12 million additional courses. BARDA’s previous Request for Proposal on this subject, number 09-35, has been cancelled. Responses to the new Request for Proposal are due February 28, 2011.
